Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/25476
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2022-03-31T07:15:38Z-
dc.date.available2022-03-31T07:15:38Z-
dc.date.issued2008-07-28-
dc.identifier.citationCansev, M. vd. (2008). "Choline, CDP-choline or phosphocholine increases plasma glucagon in rats: Involvement of the peripheral autonomic nervous system". European Journal of Pharmacology, 589(1-3), 315-322.en_US
dc.identifier.issn0014-2999-
dc.identifier.urihttps://doi.org/10.1016/j.ejphar.2008.05.017-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S001429990800561X-
dc.identifier.urihttp://hdl.handle.net/11452/25476-
dc.description.abstractThe present study was designed to test the effects of choline, cytidine-5'-diphosphocholine (CDP-choline) and phosphocholine on plasma glucagon concentrations in rats. Intraperitoneal (i.p.) injection of 200-600 mu mol/kg of choline, CDP-choline or phosphocholine produced a dose-dependent increase in plasma glucagon and choline concentrations. Pretreatment with hexamethonium (15 mg/kg: i.p.), a peripherally-acting ganglionic nicotinic acetylcholine receptor antagonist, entirely blocked the increases in plasma glucagon by 600 mu mol/kg of choline, CDP-choline or phosphocholine. The increases in plasma glucagon by these choline compounds was reduced significantly (P<0.01) by about 25% by pretreatment with atropine methylnitrate (2 mg/kg), a peripherally-acting muscarinic acetylcholine receptor antagonist. Blockade of central acetylcholine receptors did not alter the increase in plasma glucagon induced by i.p. choline (600 mu mol/kg). While alpha(2)-adrenoceptor blockade or bilateral adrenalectomy attenuated the increase in plasma glucagon evoked by choline compounds, blockade of alpha(1)- or beta-adrenoceptors or chemical sympathectomy failed to alter this increase. Intracerebroventricular (i.c.v.) choline (1.5 mu mol) administration also increased plasma glucagon; the effect was blocked by central pretreatment with a neuronal type nicotinic acetylcholine receptor antagonist, mecamylamine (50 mu g; i.c.v.) or the neuronal choline uptake inhibitor, hemicholinium-3 (20 mu g; i.c.v.). These data show that choline, CDP-choline or phosphocholine increases plasma glucagon concentrations by increasing peripheral nicotinic and muscarinic cholinergic neurotransmissions. Central choline also increases plasma glucagon by augmenting central nicotinic cholinergic neurotransmission by acting presynaptically. Stimulation of adrenal medullary catecholamine release and subsequent activation of alpha(2)-adrenoceptors are mainly involved in the increase in plasma glucagon induced by choline, CDP-choline or phosphocholine.en_US
dc.description.sponsorshipTUBAtr_TR
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectAdrenoceptoren_US
dc.subjectCatecholamineen_US
dc.subjectCDP-cholineen_US
dc.subjectCholineen_US
dc.subjectGlucagonen_US
dc.subjectPhosphocholineen_US
dc.subjectNicotinic acetylcholine-receptorsen_US
dc.subjectSympathoadrenal systemen_US
dc.subjectTyrosine-hydroxylaseen_US
dc.subjectBlood-pressureen_US
dc.subjectSerum-insulinen_US
dc.subjectSecretionen_US
dc.subjectActivationen_US
dc.subjectHyperglycemiaen_US
dc.subjectMetabolitesen_US
dc.subjectReleaseen_US
dc.subject.meshAdrenal medullaen_US
dc.subject.meshAdrenalectomyen_US
dc.subject.meshAdrenergic alpha-antagonistsen_US
dc.subject.meshAdrenergic beta-antagonistsen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAutonomic nervous systemen_US
dc.subject.meshBrainen_US
dc.subject.meshCholineen_US
dc.subject.meshCytidine diphosphate cholineen_US
dc.subject.meshDose-response relationship, drugen_US
dc.subject.meshGlucagonen_US
dc.subject.meshInjections, intraperitonealen_US
dc.subject.meshInjections, intraventricularen_US
dc.subject.meshMuscarinic antagonistsen_US
dc.subject.meshNeurotransmitter uptake inhibitorsen_US
dc.subject.meshMuscarinic antagonistsen_US
dc.subject.meshNicotinic antagonistsen_US
dc.subject.meshPhosphorylcholineen_US
dc.subject.meshRatsen_US
dc.subject.meshRats, sprague-dawleyen_US
dc.subject.meshSympathectomy, chemicalen_US
dc.subject.meshTime factorsen_US
dc.subject.meshUp-regulationen_US
dc.subject.meshGanglionic blockersen_US
dc.titleCholine, CDP-choline or phosphocholine increases plasma glucagon in rats: Involvement of the peripheral autonomic nervous systemen_US
dc.typeArticleen_US
dc.identifier.wos000258628400052tr_TR
dc.identifier.scopus2-s2.0-47549099175tr_TR
dc.relation.tubitakT-2003/50tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Farmakoloji ve Klinik Farmakoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0001-9496-1475tr_TR
dc.contributor.orcid0000-0003-2918-5064tr_TR
dc.identifier.startpage315tr_TR
dc.identifier.endpage322tr_TR
dc.identifier.volume589tr_TR
dc.identifier.issue1-3tr_TR
dc.relation.journalEuropean Journal of Pharmacologyen_US
dc.contributor.buuauthorCansev, Mehmet-
dc.contributor.buuauthorİlçöl, Yeşim Özarda-
dc.contributor.buuauthorYılmaz, Mustafa Sertaç-
dc.contributor.buuauthorHamurtekin, Emre-
dc.contributor.buuauthorUlus, İsmail Hakki-
dc.contributor.researcheridM-9071-2019tr_TR
dc.contributor.researcheridAAH-1571-2021tr_TR
dc.contributor.researcheridD-5340-2015tr_TR
dc.contributor.researcheridAAL-8873-2021tr_TR
dc.identifier.pubmed18561911tr_TR
dc.subject.wosPharmacology & pharmacyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ2en_US
dc.contributor.scopusid8872816100tr_TR
dc.contributor.scopusid35741320500tr_TR
dc.contributor.scopusid8895544100tr_TR
dc.contributor.scopusid8717648500tr_TR
dc.contributor.scopusid7004271086tr_TR
dc.subject.scopusCiticoline; Neuroprotective Agents; Glycerylphosphorylcholineen_US
dc.subject.emtreeAtropine methyl nitrateen_US
dc.subject.emtreeCholineen_US
dc.subject.emtreeCiticolineen_US
dc.subject.emtreeGlucagonen_US
dc.subject.emtreeHemicholinium 3en_US
dc.subject.emtreeHexamethoniumen_US
dc.subject.emtreeMecamylamineen_US
dc.subject.emtreePhosphorylcholineen_US
dc.subject.emtreeAdrenalectomyen_US
dc.subject.emtreeAlpha adrenergic receptor blockingen_US
dc.subject.emtreeAnimal experimenten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeAutonomic nervous systemen_US
dc.subject.emtreeCholinergic systemen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDose responseen_US
dc.subject.emtreeGlucagon blood levelen_US
dc.subject.emtreeGlucagon releaseen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNeuroendocrinologyen_US
dc.subject.emtreeNonhumanen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeRaten_US
Appears in Collections:PubMed
Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.